Porphyria prevention study halted early
NCT ID NCT02922413
First seen Feb 01, 2026 · Last updated Jun 02, 2026 · Updated 25 times
Summary
This study tested whether Panhematin (hemin) could safely prevent acute attacks in people with certain types of porphyria. It enrolled 13 adults with acute intermittent porphyria, hereditary coproporphyria, or variegate porphyria. Participants received either Panhematin or a placebo, and researchers tracked attacks and serious side effects. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE INTERMITTENT PORPHYRIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas Medical Branch
Galveston, Texas, 77555, United States
Conditions
Explore the condition pages connected to this study.